1887

Journal of General Virology header logo

Volume 86, Issue 6

Stable human lymphoblastoid cell lines constitutively expressing hepatitis C virus proteins Free

Abstract

The cellular immune response plays a central role in virus clearance and pathogenesis of liver disease in hepatitis C. The study of hepatitis C virus (HCV)-specific immune responses is limited by currently available cell-culture systems. Here, the establishment and characterization of stable human HLA-A2-positive B-lymphoblastoid×T hybrid cell lines constitutively expressing either the NS3–4A complex or the entire HCV polyprotein are reported. These cell lines, termed T1/NS3-4A and T1/HCVcon, respectively, were maintained in continuous culture for more than 1 year with stable characteristics. HCV structural and non-structural proteins were processed accurately, indicating that the cellular and viral proteolytic machineries are functional in these cell lines. Viral proteins were found in the cytoplasm in dot-like structures when expressed in the context of the HCV polyprotein or in a perinuclear fringe when the NS3–4A complex was expressed alone. T1/NS3-4A and T1/HCVcon cells were lysed efficiently by HCV-specific cytotoxic T lymphocytes from patients with hepatitis C and from human HLA-A2.1 transgenic mice immunized with a liposomal HCV vaccine, indicating that viral proteins are processed endogenously and presented efficiently via the major histocompatibility complex class I pathway. In conclusion, these cell lines represent a unique tool to study the cellular immune response, as well as to evaluate novel vaccine and immunotherapeutic strategies against HCV.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.80853-0
2005-06-01
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/jgv/86/6/vir861737.html?itemId=/content/journal/jgv/10.1099/vir.0.80853-0&mimeType=html&fmt=ahah

References

  1. Baum C., Forster P., Hegewisch-Becker S., Harbers K. 1994; An optimized electroporation protocol applicable to a wide range of cell lines. Biotechniques 17:1058–1062
     [Google Scholar]
  2. Boisvert J., He X.-S., Cheung R., Keeffe E. B., Wright T., Greenberg H. B. 2001; Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver. J Infect Dis 184:827–835 [CrossRef]
     [Google Scholar]
  3. Brass V., Bieck E., Montserret R., Wölk B., Hellings J. A., Blum H. E., Penin F., Moradpour D. 2002; An amino-terminal amphipathic α -helix mediates membrane association of the hepatitis C virus nonstructural protein 5A. J Biol Chem 277:8130–8139 [CrossRef]
     [Google Scholar]
  4. Cerny A., Chisari F. V. 1999; Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 30:595–601 [CrossRef]
     [Google Scholar]
  5. Cerny A., McHutchison J. G., Pasquinelli C., Brown M. E., Brothers M. A., Grabscheid B., Fowler P., Houghton M., Chisari F. V. 1995; Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 95:521–530 [CrossRef]
     [Google Scholar]
  6. Chen M., Shirai M., Liu Z., Arichi T., Takahashi H., Nishioka M. 1998; Efficient class II major histocompatibility complex presentation of endogenously synthesized hepatitis C virus core protein by Epstein-Barr virus-transformed B-lymphoblastoid cell lines to CD4+ T cells. J Virol 72:8301–8308
     [Google Scholar]
  7. Cooper S., Erickson A. L., Adams E. J., Kansopon J., Weiner A. J., Chien D. Y., Houghton M., Parham P., Walker C. M. 1999; Analysis of a successful immune response against hepatitis C virus. Immunity 10:439–449 [CrossRef]
     [Google Scholar]
  8. DeMars R., Chang C. C., Shaw S., Reitnauer P. J., Sondel P. M. 1984; Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Hum Immunol 11:77–97 [CrossRef]
     [Google Scholar]
  9. De Vita S., De Re V., Sansonno D. 7 other authors 2002; Lack of HCV infection in malignant cells refutes the hypothesis of a direct transforming action of the virus in the pathogenesis of HCV-associated B-cell NHLs. Tumori 88:400–406
     [Google Scholar]
  10. Diepolder H. M., Zachoval R., Hoffmann R. M., Wierenga E. A., Santantonio T., Jung M.-C., Eichenlaub D., Pape G. R. 1995; Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346:1006–1007 [CrossRef]
     [Google Scholar]
  11. Dubuisson J., Hsu H. H., Cheung R. C., Greenberg H. B., Russell D. G., Rice C. M. 1994; Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 68:6147–6160
     [Google Scholar]
  12. Egger D., Wölk B., Gosert R., Bianchi L., Blum H. E., Moradpour D., Bienz K. 2002; Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 76:5974–5984 [CrossRef]
     [Google Scholar]
  13. Engelhard V. H., Brickner A. G., Zarling A. L. 2002; Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire. Mol Immunol 39:127–137 [CrossRef]
     [Google Scholar]
  14. Engler O. B., Schwendener R. A., Dai W. J., Wölk B., Pichler W., Moradpour D., Brunner T., Cerny A. 2004; A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine 23:58–68 [CrossRef]
     [Google Scholar]
  15. Firat H., Garcia-Pons F., Tourdot S. 11 other authors 1999; H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol 29:3112–3121 [CrossRef]
     [Google Scholar]
  16. Forns X., Bukh J., Purcell R. H. 2002; The challenge of developing a vaccine against hepatitis C virus. J Hepatol 37:684–695 [CrossRef]
     [Google Scholar]
  17. Gosert R., Egger D., Lohmann V., Bartenschlager R., Blum H. E., Bienz K., Moradpour D. 2003; Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 77:5487–5492 [CrossRef]
     [Google Scholar]
  18. Grakoui A., Wychowski C., Lin C., Feinstone S. M., Rice C. M. 1993; Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 67:1385–1395
     [Google Scholar]
  19. Gremion C., Grabscheid B., Wölk B., Moradpour D., Reichen J., Pichler W., Cerny A. 2004; Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol 78:2152–2157 [CrossRef]
     [Google Scholar]
  20. Hanada K., Yewdell J. W., Yang J. C. 2004; Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427:252–256 [CrossRef]
     [Google Scholar]
  21. Kammer A. R., van der Burg S. H., Grabscheid B., Hunziker I. P., Kwappenberg K. M. C., Reichen J., Melief C. J. M., Cerny A. 1999; Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 190:169–176 [CrossRef]
     [Google Scholar]
  22. Kolykhalov A. A., Agapov E. V., Blight K. J., Mihalik K., Feinstone S. M., Rice C. M. 1997; Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277:570–574 [CrossRef]
     [Google Scholar]
  23. Kumar A., Kang Y.-H., Gowda K., Mullen C. A., Gordon D. M., Kumar S., Hoffman S. L. 1997; Autologous lymphoblastoid cell lines stably transfected with Plasmodium falciparum circumsporozoite protein as targets in cytotoxic T-lymphocyte assays. Immunol Lett 55:183–187 [CrossRef]
     [Google Scholar]
  24. Laskus T., Radkowski M., Piasek A., Nowicki M., Horban A., Cianciara J., Rakela J. 2000; Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 181:442–448 [CrossRef]
     [Google Scholar]
  25. Lauer G. M., Ouchi K., Chung R. T. 8 other authors 2002; Comprehensive analysis of CD8+-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol 76:6104–6113 [CrossRef]
     [Google Scholar]
  26. Lechner F., Gruener N. H., Urbani S. 8 other authors 2000; CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol 30:2479–2487 [CrossRef]
     [Google Scholar]
  27. Lerat H., Rumin S., Habersetzer F., Berby F., Trabaud M.-A., Trépo C., Inchauspé G. 1998; In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood 91:3841–3849
     [Google Scholar]
  28. Missale G., Bertoni R., Lamonaca V. 7 other authors 1996; Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98:706–714 [CrossRef]
     [Google Scholar]
  29. Moradpour D., Englert C., Wakita T., Wands J. R. 1996; Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 222:51–63 [CrossRef]
     [Google Scholar]
  30. Moradpour D., Kary P., Rice C. M., Blum H. E. 1998; Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. Hepatology 28:192–201
     [Google Scholar]
  31. Moradpour D., Grabscheid B., Kammer A. R., Schmidtke G., Groettrup M., Blum H. E., Cerny A. 2001; Expression of hepatitis C virus proteins does not interfere with major histocompatibility complex class I processing and presentation in vitro. Hepatology 33:1282–1287 [CrossRef]
     [Google Scholar]
  32. Moradpour D., Bieck E., Hügle T., Wels W., Wu J. Z., Hong Z., Blum H. E., Bartenschlager R. 2002; Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 277:593–601 [CrossRef]
     [Google Scholar]
  33. National Institutes of Health 2002; National Institutes of Health Consensus Development Conference statement: management of hepatitis C. Hepatology 36:S3–S20
     [Google Scholar]
  34. Park B., Kim Y., Shin J., Lee S., Cho K., Früh K., Lee S., Ahn K. 2004; Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity 20:71–85 [CrossRef]
     [Google Scholar]
  35. Pietschmann T., Bartenschlager R. 2003; Tissue culture and animal models for hepatitis C virus. Clin Liver Dis 7:23–43 [CrossRef]
     [Google Scholar]
  36. Retière C., Prod'homme V., Imbert-Marcille B.-M., Bonneville M., Vié H., Hallet M.-M. 2000; Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response. J Virol 74:3948–3952 [CrossRef]
     [Google Scholar]
  37. Rotzschke O., Falk K., Stevanovic S., Jung G., Walden P., Rammensee H. G. 1991; Exact prediction of a natural T cell epitope. Eur J Immunol 21:2891–2894 [CrossRef]
     [Google Scholar]
  38. Salter R. D., Howell D. N., Cresswell P. 1985; Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21:235–246 [CrossRef]
     [Google Scholar]
  39. Sansonno D., De Vita S., Iacobelli A. R., Cornacchiulo V., Boiocchi M., Dammacco F. 1998a; Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 160:3594–3601
     [Google Scholar]
  40. Sansonno D., Lotesoriere C., Cornacchiulo V., Fanelli M., Gatti P., Iodice G., Racanelli V., Dammacco F. 1998b; Hepatitis C virus infection involves CD34+ hematopoietic progenitor cells in hepatitis C virus chronic carriers. Blood 92:3328–3337
     [Google Scholar]
  41. Schirle M., Keilholz W., Weber B., Gouttefangeas C., Dumrese T., Becker H. D., Stevanovic S., Rammensee H. G. 2000; Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 30:2216–2225 [CrossRef]
     [Google Scholar]
  42. Schmidt-Mende J., Bieck E., Hügle T., Penin F., Rice C. M., Blum H. E., Moradpour D. 2001; Determinants for membrane association of the hepatitis C virus RNA-dependent RNA polymerase. J Biol Chem 276:44052–44063 [CrossRef]
     [Google Scholar]
  43. Shoukry N. H., Cawthon A. G., Walker C. M. 2004; Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 58:391–424 [CrossRef]
     [Google Scholar]
  44. Sung V. M.-H., Shimodaira S., Doughty A. L., Picchio G. R., Can H., Yen T. S. B., Lindsay K. L., Levine A. M., Lai M. M. C. 2003; Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 77:2134–2146 [CrossRef]
     [Google Scholar]
  45. Takaki A., Wiese M., Maertens G., Depla E., Seifert U., Liebetrau A., Miller J. L., Manns M. P., Rehermann B. 2000; Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6:578–582 [CrossRef]
     [Google Scholar]
  46. Thimme R., Bukh J., Spangenberg H. C., Wieland S., Pemberton J., Steiger C., Govindarajan S., Purcell R. H., Chisari F. V. 2002; Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 99:15661–15668 [CrossRef]
     [Google Scholar]
  47. Ureta-Vidal A., Firat H., Pérarnau B., Lemonnier F. A. 1999; Phenotypical and functional characterization of the CD8+ T cell repertoire of HLA-A2.1 transgenic, H-2Kb0Db0 double knockout mice. J Immunol 163:2555–2560
     [Google Scholar]
  48. Wertheimer A. M., Miner C., Lewinsohn D. M., Sasaki A. W., Kaufman E., Rosen H. R. 2003; Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 37:577–589 [CrossRef]
     [Google Scholar]
  49. Whitmore M. M., Li S., Falo L. Jr, Huang L. 2001; Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol Immunother 50:503–514 [CrossRef]
     [Google Scholar]
  50. Wölk B., Sansonno D., Kräusslich H.-G., Dammacco F., Rice C. M., Blum H. E., Moradpour D. 2000; Subcellular localization, stability, and trans -cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol 74:2293–2304 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.80853-0
Loading
Stable human lymphoblastoid cell lines constitutively expressing hepatitis C virus proteins
J. Gen. Virol. 86, 1737 (2005); https://doi.org/10.1099/vir.0.80853-0
/content/journal/jgv/10.1099/vir.0.80853-0
/content/journal/jgv/10.1099/vir.0.80853-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error